ArticleOncoimmunology2020
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 66 citations in OpenAlex.
- Optimizing immunotherapy for head and neck squamous cell carcinoma: recent advances and future directions.Annals of medicine · 2026Review
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.ESMO open · 2026Article
- GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.Molecular cancer therapeutics · 2026Article
- VISTA: bridging gaps in cancer immunotherapy.Discover oncology · 2026Review
- Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies.Seminars in cancer biology · 2025Review
- Dual membrane receptor degradation via folate receptor targeting chimera.Nature communications · 2025Article
- Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection.NPJ precision oncology · 2025Article
- A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.Cancer biology & therapy · 2024Review
- The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal Carcinoma.Diagnostics (Basel, Switzerland) · 2024Article
- Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment.Cancers · 2024Review
- Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee.Journal for immunotherapy of cancer · 2024Review
- Identification of RFC4 as a potential biomarker for pan-cancer involving prognosis, tumour immune microenvironment and drugs.Journal of cellular and molecular medicine · 2024Article
- Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer.International journal of molecular sciences · 2024Article
- Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown.Molecular oncology · 2024Article
- Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting.American journal of cancer research · 2024Article
- Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.Cancer medicine · 2024Article
- TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer.American journal of cancer research · 2024Article
- The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types.American journal of cancer research · 2024Article
- Trial watch: anticancer vaccination with dendritic cells.Oncoimmunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order to understand the immune landscape of metastatic malignancies as well as anti-PD-1/PD-L1 inhibitor resistance mechanisms. Interrogation of 51 markers of the cancer-immunity cycle was performed in 101 patients with diverse malignancies using a clinical-grade RNA sequencing assay. Overall, the immune phenotypes demonstrated overexpression of multiple checkpoints including VISTA (15.8% of 101 patients), PD-L2 (10.9%), TIM3 (9.9%), LAG3 (8.9%), PD-L1 (6.9%) and CTLA4 (3.0%). Additionally, aberrant expression of macrophage-associated markers (e.g. CD68 and CSF1R; 11-23%), metabolic immune escape markers (e.g. ADORA2A and IDO1; 9-16%) and T-cell priming markers (e.g. CD40, GITR, ICOS and OX40; 4-31%) were observed. Most tumors (87.1%, 88/101) expressed distinct immune portfolios, with a median of six theoretically actionable biomarkers (pharmacologically tractable by Food and Drug Administration approved agents [on- or off-label] or with agents in clinical development). Overexpression of TIM-3, VISTA and CD68 were significantly associated with shorter progression-free survival (PFS) after anti-PD-1/PD-L1-based therapies (among 39 treated patients) (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.